News | July 29, 2024
Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Combined entity is better positioned to compete in increasingly competitive generics industry
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Cipla completes transfer of Generics Business Undertaking
BHL will undertake the development and supply of these molecules
Subscribe To Our Newsletter & Stay Updated
